A method of wet-scrubbing a waste gas containing sulfur dioxide (SO.sub.2) to produce potassium thiosulfate. The wet-scrubbing facility includes multiple horizontally disposed stages where a preceding stage passes partially-scrubbed waste gas to a succeeding stage. Each stage has a scrubber mechanism to scrub waste gas with circulating fluid that progressively reduces SO.sub.2 in the waste gas before atmospheric discharge. The scrubber mechanism may optionally include a packing material to facilitate absorption of SO.sub.2 by the fluid, a sump disposed at the output of the stage to receive fluid as it drains from the packing, and a circulation pump to circulate fluid from the sump to its packing and to cascade at least a portion of the fluid back to a preceding stage. A portion of the fluid is extracted and reacted in a reaction vessel with a cation to produce potassium thiosulfate.

A method of wet-scrubbing a waste gas containing sulfur dioxide (SO.sub.2) to produce potassium thiosulfate. The wet-scrubbing facility includes multiple horizontally disposed stages where a preceding stage passes partially-scrubbed waste gas to a succeeding stage. Each stage has a scrubber mechanism to scrub waste gas with circulating fluid that progressively reduces SO.sub.2 in the waste gas before atmospheric discharge. The scrubber mechanism may optionally include a packing material to facilitate absorption of SO.sub.2 by the fluid, a sump disposed at the output of the stage to receive fluid as it drains from the packing, and a circulation pump to circulate fluid from the sump to its packing and to cascade at least a portion of the fluid back to a preceding stage. A portion of the fluid is extracted and reacted in a reaction vessel with a cation to produce potassium thiosulfate.

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.